Hydra Biosciences, Inc.

Ariad Pharmaceuticals, Inc.

Proteotech Inc.

Other

Eli Lilly and Company

Manfred Weigele

Jayhong A Chong

Glenn R Larsen

Christopher Fanger

Amy Ripka

Magdalene M Moran

Dennis John Underwood

Xiaoguang Zhen

Alan D Snow

Thomas P Lake

William C Lumma

Tomi K Sawyer

Peter C Meltzer

Joel Cummings

Luke A Esposito

F Michael Hudson

Anu Mahadevan

Howard P Ng

William C Shakespeare

Yihan Wang

Chester A Metcalf, Iii

David C Dalgarno

Rajeswari Sundaramoorthi

Regine Bohacek

Lesley Larsen

Gerardo M Castillo

Steven P Adams

Michael G Yang

Terence P Keenan

Beth P Nguyen

John D Iuliucci

Berkley A Lynch

Noriyuki H Kawahata

Mallory F Loewe

Christopher S Poss

Virginia A Jacobsen

Karina Macek

Craig S Takeuchi

George P Luke

Neil Hayward

Donato Del Camino

Howard Ng

The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

Compounds for modulating TRPV3 function

Compounds of modulating TRPV3 function

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions, and methods for the treatment of &#x3b2;-amyloid diseases and synucleinopathies

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies

The present application relates to compounds of Formula I as defined herein, and methods for treating pain and other conditions related to TRPV3.

Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function

Compounds and compositions for treating disorders related to TRPA1 are described herein.

Methods and compositions for treating disorders

The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. Suitable compounds include but are not limited to, for example, substituted quinazolin-4-ones of formula I.

Substituted quinazolin-4-one compounds for antagonizing TRPV3 function

Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies

This invention relates to compounds of the general formula: in which R, R, Rand Rare as defined herein, and to their preparation and use. In these compounds, Ris an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety which comprises one or more phosphorus-containing moieties.

Purine derivatives

This invention concerns compounds for inhibiting intracellular signal transduction, especially intracellular signal transduction mediate by one or more molecular interactions involving a phosphotyrosine-containing protein. This invention also relates to pharmaceutic compositions containing the compounds and prophylactic and therapeutic methods involving pharmaceutical and veterinary administration of the compounds. The compounds are of formula (1) as defined herein.

Signal transduction inhibitors, compositions containing them

Growing community of inventors

Cambridge, MA, United States of America

Manfred Weigele